IP Library › Granted Patent US 11,701,386
Granted Patent B2
US 11,701,386 · App. 16/646,906 · Granted Jul 18, 2023

Cell

Inventors: Martin Pulé (London, GB); Shaun Cordoba (London, GB); Simon Thomas (London, GB); Shimobi Onuoha (London, GB); Matteo Righi (London, GB)
Assignee: AUTOLUS LIMITED
A61K35/17C07K14/4705C07K14/705C12N15/62C07K2319/02C07K2319/20C07K2319/50C07K2319/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,701,386
App. No.
16/646,906
Granted
Jul 18, 2023
Kind
B2
Abstract

The present invention relates to a cell comprising a chimeric antigen receptor (CAR) and a constitutively active or inducible Signal Transducer and Activator of Transcription (STAT) molecule.

Claims (15)

1. An engineered cell which comprises a CAR and a constitutively active Signal Transducer and Activator of Transcription (STAT) molecule,

wherein the constitutively active STAT molecule is

(a) a dimerized and constitutively active STAT molecule comprising a first STAT polypeptide having a first dimerization domain and a second STAT polypeptide having a second dimerization domain which second dimerization domain specifically binds the first dimerization domain and wherein the dimerization of the first and second STAT polypeptides structurally changes the STAT molecule to a constitutively active form,

(b) a constitutively active STAT molecule comprising a first STAT polypeptide linked to a second STAT polypeptide by a linker sequence, or

(c) a constitutively active STAT molecule comprising a Gain of Function (GOF) mutation.

2. A cell according to claim 1 (b).

3. A cell according to claim 1 (a).

4. A nucleotide construct comprising a first nucleotide sequence encoding a CAR and a second nucleotide sequence encoding a constitutively active STAT molecule,

wherein the constitutively active STAT molecule is

(a) a dimerized and constitutively active STAT molecule comprising a first STAT polypeptide having a first dimerization domain and a second STAT polypeptide having a second dimerization domain which second dimerization domain specifically binds the first dimerization domain and wherein the dimerization of the first and second STAT polypeptides structurally changes the STAT molecule to a constitutively active form,

(b) a constitutively active STAT molecule comprising a first STAT polypeptide linked to a second STAT polypeptide by a linker sequence, or

(c) a constitutively active STAT molecule comprising a Gain of Function (GOF) mutation.

5. A pharmaceutical composition comprising a plurality of cells according to claim 1 .

6. A method for making a cell according to claim 1 , which comprises the step of introducing into a cell a nucleic acid sequence encoding the constitutively active or inducible STAT molecule.

7. A cell according to claim 1 (c).

Assignments (2)
PATENT SECURITY AGREEMENT Recorded Jul 30, 2026
From: AUTOLUS LIMITED
To: PERCEPTIVE CREDIT HOLDINGS V, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 076084/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2020
From: PULÉ, MARTIN; CORDOBA, SHAUN; THOMAS, SIMON; ONUOHA, SHIMOBI; RIGHI, MATTEO
To: AUTOLUS LIMITED
Reel/Frame 052162/0248 →
Priority Claims (1)
GB 1714718 · Sep 13, 2017 · national
Continuity (1)
Related Publication 20200297766A1 · Sep 24, 2020
Cited By (1)
US 12,269,860